

NWL REWIND Type 2 Diabetes Pathways

(REWIND: **RE**ducing **W**eight with **IN**tensive **D**ietary support)

Inclusion, Exclusion Criteria, Coding, Medication Protocols


v2.03 December 2020



NWL REWIND Type 2 Diabetes Simplified Pathway

This slide is a one page summary of the next two pages

* Codes used are SNOMED (SystmOne) and READv2 (EMIS)



UK ICS REWIND PROVIDER

Provider contact patient and hold initial assessment (IA). Patient agrees diet pathway (TDR or Low Carb), confirms diet start date and informed to contact GP to arrange monitoring and de-prescribing

Primary care team contact patient, issue glucometer and stop repeat medication on clinical system according to guidelines, arrange reviews at weeks 1 & 2 and at 1,2 & 3 months

Patient starts programme – Run by UK ICS

Coding:

- Very low energy diet (226079002 or 8B5C0)* **AND**
- Healthy lifestyle programme commenced (377531000000108 or 9m40.)

Coding:

- Carbohydrate restricted diet (66539004 or 13B5.) **AND**
- Healthy lifestyle programme commenced (377531000000108 or 9m40.)

1, 2, 4 and 8 week primary care follow up:
Blood pressure, Check glucometer readings (supported by HCA or self reporting)

Patient completes or drops out of programme

12 month primary care follow up:
HbA1c, Blood pressure, Lipids, Body mass index

Healthy lifestyle programme completed (377621000000107 or 9m42.) **OR**
Healthy lifestyle programme not completed (377591000000109 or 9m41.)



NWL REWIND Type 2 Diabetes Detailed Referral Pathway

PRIMARY CARE INVITATION

Inclusion criteria:

- Age 18 or over and registered with NWL GP;
- Diabetes duration < 12 years (in phase 1);
- HbA1c within the last 12 months:
 - HbA1c 43-87 mmol/mol **with** diabetes medication;
 - HbA1c 48-87 mmol/mol **without** diabetes medication;
 - Latest HbA1c 88-108mmol/mol if:
 - patient is within 6 months of diagnosis **OR**
 - retinal screening within past 6/12 with no evidence of untreated proliferative or pre-proliferative retinopathy and potential impact discussed with service user. Retinal screening 6m after programme start if HbA1c improves > 25mmol/mol)

Exclusions for Both Pathways:

- HbA1c > 108mmol/mol;
- Current insulin use (at least in phase 1);
- Pregnant or planning to become pregnant during next 6 months. Defer those breastfeeding until lactation ceases;
- Severe renal impairment (eGFR <30);
- Health professional assessment that the person is unlikely to understand or meet the demands of the treatment programme and/or monitoring requirements (e.g. active psychotic illness or severe depression requiring psychiatric review);
- Unwilling to provide blood samples;
- Unwilling to allow sharing of clinical information with WSIC

Send REWIND **Invitation SMS** or offer at diabetes appointment

Patient contacts GP

GP/HCP sends referral (populated with inclusion/exclusion criteria) after checking eligibility and suitability

Coding for referral: Referral to healthy lifestyle programme (892281000000101 or 8Hlu.)

UK ICS REWIND PROVIDER

Patient attends provider initial assessment and agrees to start programme

Patient encouraged to follow Total Diet Replacement (TDR) pathway, but if unwilling or meets exclusion criteria, then offered Low Carb pathway

Specific Exclusions for TDR:

- BMI of under 27kg/m² (adjusted to 25kg/m² in people of South Asian and Chinese origin);
- Significant physical co-morbidities:
 - active cancer other than skin cancer treated with curative intent by local treatment only, or people taking hormonal or other long term secondary prevention;
 - heart attack or stroke in last 6 months;
 - severe heart failure;
 - active liver disease (not including NAFLD);
- Active substance use disorder/eating disorder;
- Porphyria;
- Known untreated proliferative or pre-proliferative retinopathy if HbA1c 87-108mmol/mol;
- Current treatment with anti-obesity drugs (would need to stop);
- Recent weight loss > 5% body weight / on current weight management programme / had or awaiting bariatric surgery (unless willing to come off waiting list)

Specific Exclusions for Low Carb Diet (<130g/day):

- Concurrent SGLT2 inhibitor usage (**SGLT-2 inhibitors will need to be stopped in view of potential risk of ketoacidosis whilst on intensive carb reduction programme**);

NWL REWIND Type 2 Diabetes Detailed Management Pathway

PRIMARY CARE SUPPORT

Prescribing management and monitoring support as needed, costed at £58.67 per patient on DPP-4, SGLT-2 or GLP-1 medication who start the programme

GP/HCP notified of start date

TOTAL DIET REPLACEMENT	LOW CARB DIET
Primary care team contact patient, issue glucometer and stop repeat diabetes (except Metformin) and BP medication on clinical system according to guidelines, arrange reviews at weeks 1 & 2 and at 1, 2 & 3 months	Primary care team contact patient, issue glucometer and stop repeat diabetes medication (except Metformin) on clinical system according to guidelines, arrange reviews at weeks 1 & 2 and at 1, 2 & 3 months
Coding: <ul style="list-style-type: none"> Very low energy diet 226079002 or 8B5C0) AND Healthy lifestyle programme commenced (377531000000108 or 9m40.) 	Coding: <ul style="list-style-type: none"> Carbohydrate restricted diet (66539004 or 13B5.) AND Healthy lifestyle programme commenced (377531000000108 or 9m40.)
1, 2, 4 and 8 week primary care follow up: Blood pressure, Check glucometer readings (supported by HCA or self reporting)	
3 and 6 month primary care follow up: HbA1c, Blood pressure, Body mass index	
12 month primary care follow up: HbA1c, Blood pressure, Lipids, Body mass index	
Healthy lifestyle programme completed (377621000000107 / 9m42.) OR Healthy lifestyle programme not completed (377591000000109 / 9m41.)	

UK ICS REWIND PROVIDER

Patient attends IA, agrees start date and informed to make de-prescribing appointment with GP

12 month intensive lifestyle programme

TOTAL DIET REPLACEMENT	LOW CARB DIET
<p>Weeks 1-12</p> <p>Primary care notified if patient drops out or does not lose weight in order to restart medication. Patient is communicated to by UKICS as a reminder to notify GP/relevant HCP of this. UKICS will send GP practice quarterly reports with list of patients at different stages.</p>	
<p>Weeks 13-24</p>	
<p>Weeks 25-52</p>	

Total Diet Replacement: Primary Care Prescribing Protocol

BASELINE	ELIGIBILITY	Check inclusion / exclusion criteria
	BASELINE METRICS	HbA1c, BP and BMI within 3 months
	GLUCOMETER	Issue glucometer with 50 strips. Ensure that patient knows how to self-test and when to seek help
DAY 1	DIABETES MEDICATIONS	People on 1-2 glucose-lowering agents should stop these agents on the first day of TDR
		People on ≥ 3 agents should stay on metformin only (or, if not taking metformin as it is contraindicated / not tolerated, stay on an oral agent which is safe with TDR, e.g. DPP4 inhibitor or pioglitazone) and stop the remaining glucose-lowering agents on the first day of TDR
		Sulfonylureas, meglitinides, SGLT2 inhibitors are not safe with TDR and MUST be stopped on the first day of TDR
DAY 1	ANTIHYPERTENSIVES	IF BP > 140/80 , CONTINUE Antihypertensive medication
		IF BP ≤ 140/80 , STOP ONE Antihypertensive medication. Order for STOPPING medication: Alpha blocker (if prescribed for hypertension) Beta blocker (continue if used for heart failure/post MI) Amiloride / Spironolactone (continue spironolactone if used for heart failure) Thiazide or thiazide-like diuretic or Calcium channel blocker ACEI or ARB (if hypertension only), consider only REDUCING dose if heart failure, previous MI or raised ACR
	LIPID MEDICATIONS	CONTINUE Fibrate, Statin, Ezetimibe
WEEK 1 & 2	CHECK BP, Review glucometer readings	If systolic BP > 165mmHg on repeated measurement RESTART one drug (see below) If significant osmotic symptoms (thirst, polyuria) or random capillary glucose is > 15 mmol/L , check that weight loss is as anticipated. If it is not, discuss whether any other help needed with diet. If weight loss is satisfactory but blood glucose is still high, consider introducing an oral hypoglycaemic agent. Start at the lowest dose and increase gradually. If blood glucose remains high, titrate or add further agents
MONTHS 1 & 2	CHECK BP, Review glucometer readings	TITRATE antihypertensive medication to achieve target BP of ≤ 130-140/80
MONTH 3	CHECK BP, weight, HbA1c; Review glucometer readings	TITRATE antihypertensive medication to achieve target BP of ≤ 130-140/80
MONTH 6	CHECK BP, weight, HbA1c; Review glucometer readings	TITRATE antihypertensive medication to achieve target BP of ≤ 130-140/80
MONTH 12	CHECK BP, weight, HbA1c; Review glucometer readings	TITRATE antihypertensive medication to achieve target BP of ≤ 130-140/80
HYPOGLYCAEMIC MEDICATION TITRATION If HbA1c above target or random capillary glucose consistently over 15mmol/L, restart one diabetes medication in line with NWL guidelines on Hounslow CCG Website.		ANTIHYPERTENSIVE MEDICATION TITRATION If Systolic BP > 165mmHg in weeks 1-2 or > 130-140mmHg thereafter, restart antihypertensive in line with NICE and NWL guidelines on Hounslow CCG Website.

Low Carb Diet: Primary Care Prescribing Protocol

BASELINE	ELIGIBILITY	Check inclusion / exclusion criteria
	BASELINE METRICS	HbA1c, BP and BMI within 3 months
	GLUCOMETER	Issue low cost glucometer with 50 strips as acute. Ensure that patient knows how to self-test and when to seek help
DAY 1	DIABETES MEDICATIONS	STOP Glitazone, SGLT-2 inhibitor (risk of ketoacidosis with SGLT-2)
		STOP Sulphonylurea or Meglitinide if HbA1c < 70. Monitor BMs more frequently
		CONTINUE Metformin (discuss merits with patient). Stop when target HbA1c achieved.
ANTIHYPERTENSIVES		CONTINUE DPP-4 inhibitor or GLP-1 UNTIL TARGET HbA1c REACHED. Stop when achieved. (consider changing GLP-1 inhibitor to semaglutide - cost effectiveness)
		IF BP > 120/80 , CONTINUE Antihypertensive medication
		IF BP ≤ 120/80 , STOP ONE Antihypertensive medication: Order for STOPPING medication: Alpha blocker (if prescribed for hypertension) Beta blocker (continue if used for heart failure/post MI) Amiloride / Spironolactone (continue spironolactone if used for heart failure) Thiazide or thiazide-like diuretic or Calcium channel blocker ACEI or ARB (if hypertension only), consider only REDUCING dose if heart failure, previous MI or raised ACR
LIPID MEDICATIONS	CONTINUE Fibrate, Statin, Ezetimibe	
WEEK 1 & 2	CHECK BP, Review glucometer readings	If systolic BP > 165mmHg on repeated measurement RESTART one drug (see below) If significant osmotic symptoms (thirst, polyuria) or random capillary glucose is > 15 mmol/L , check that weight loss is as anticipated. If it is not, discuss whether any other help needed with diet. If weight loss is satisfactory but blood glucose is still high, consider introducing an oral hypoglycaemic agent. Start at the lowest dose and increase gradually. If blood glucose remains high, add further agents
MONTHS 1 & 2	CHECK BP, Review glucometer readings	TITRATE antihypertensive medication to achieve target BP of ≤ 130-140/80
MONTH 3	CHECK BP, weight, HbA1c; Review glucometer readings	TITRATE antihypertensive medication to achieve target BP of ≤ 130-140/80
MONTH 6	CHECK BP, weight, HbA1c; Review glucometer readings	TITRATE antihypertensive medication to achieve target BP of ≤ 130-140/80
MONTH 12	CHECK BP, weight, HbA1c; Review glucometer readings	TITRATE antihypertensive medication to achieve target BP of ≤ 130-140/80
HYPOGLYCAEMIC MEDICATION TITRATION If HbA1c above target or random capillary glucose consistently over 15mmol/L, restart one diabetes medication in line with NWL guidelines on Hounslow CCG Website.		ANTIHYPERTENSIVE MEDICATION TITRATION If Systolic BP > 165mmHg in weeks 1-2 or > 130-140mmHg thereafter, restart antihypertensive in line with NICE and NWL guidelines on Hounslow CCG Website.

Monitoring of Blood Glucose Levels

